Immunohistochemical analysis of PAI-2 (plasminogen activator inhibitor type 2) and p53 protein in early gastric cancer patients with recurrence: A preliminary report

Japanese Journal of Clinical Oncology

Volumn 29, Issue 4, 1999, Pages 187-191

  Kammori, Makoto ^a   Kaminishi, Michio ^a   Kobayashi, Kaoru ^a   Oohara, Takeshi ^a   Endo, Hisako ^a   Takubo, Kaiyo ^b   Hashimoto, Hajime ^c  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^c Tokyo Metropolitan Institute of Gerontology   (Japan)

Author keywords

Early gastric cancer; p53 protein; Plasminogen activator inhibitor types 1 and 2; Urokinase type plasminogen activator

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN P53; UROKINASE;

ADENOCARCINOMA; AGED; ARTICLE; CHEMISTRY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PERITONEUM TUMOR; RISK; STOMACH TUMOR;

ADENOCARCINOMA; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PERITONEAL NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 2; RISK; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033111411     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/29.4.187     Document Type: Article

References (33)

1. Dano K, Anderson PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266.
2. Marutsuka K, Sujumiya J, Kataoka H, Komada N, Kohno M, Sumiyoshi A. Correlation between urokinase-type plasminogen activator production and the metastasis ability of human rectal cancer cells. Invas Metastasis 1991;11:181-91.
3. Duffy MJ, O'Grady P, Devaey D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer 1988;62:531-3.
4. Oka T, Ishida T, Nishino T, Sugimachi K. Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res 1991;51:3522-5.
5. Wang S-N, Miyauchi M, Koshikawa N, Maruyama K, Kubota T, Miura K, et al. Antigen expression associated with lymph node metastasis in gastric adenocarcinomas. Pathology Int 1994;44:844-9.
6. Feinberg RF, Kao L-C, Haimowitz JE, Queenan JT Jr, Wun TC, Strauss JF 3rd, et al. Plasminogen activator inhibitor type 1 and type 2 in human trophoblasts. Lab Invest 1989;61:20-6.
7. Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, et al. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997;79:2067-72.
8. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma, 2nd English Edition. Gastric Cancer 1998;1:10-24.
9. Duffy MJ, O'Grady P, Devaey D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive in breast carcinomas. Cancer 1988;62:531-3.
10. Nishio N, Aoki K, Tokura Y. The urokinase type of plasminogen activator in cancer of digestive tracts. Thromb Res 1988;50:527-35.
11. Ganesh S, Sier CFM, Griffioen G, Vloedgiaven HJ, de Boer A, Welvaart K, et al. Progonostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994;54:4065-71.
12. Buo L, Lyberg T, Jorgensen L, Johansen HT, Aasen AO. Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas. APMIS 1993;101:235-41.
13. Nekarda H, Schmitt M, Wenninger A, Vogelsang H, Becker K, Roder JD, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994;54:2900-7.
14. Cubellis MV, Nolli ML, Cassani G, Blasi F. Binding of single-chain pro-urokinase to the urokinase receptor on human U937 Cells. J Biol Chem 1986;261:15819-22.
15. Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surface: evidence for plasminogen and urokninase receptors on the same cell type. J Cell Biol 1986;103:2411-20.
16. Keski-Oja J, Lohi J, Tuuttila A, Tryggvason K, Vartio T. Proteolytic processing of the 72 000-Da type collagenase by urokinase plasminogen activator. Exp Cell Res 1992;202:471-6.
17. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP, et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994;344:583-4.
18. Takai S, Yamamura M, Tanaka K, Kawanishi H, Tsuji M, Nakane Y, et al. Plasminogen activator in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining. Int J Cancer 1991;48:20-7.
19. Ganesh S, Cornells FM, Griffioen G, Vloedgraven JM, der Bore A, Welvaart K, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994;54:4065-71.
20. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S. Plasminogen activator system in breast cancer. Int. J. Cancer 1992;50:345-8.
21. Bartek J, Iggo R, Gannon J, Lune DP. Genetic and immunohistochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990;5:893-9.
22. Iggo R, Gatter K, Bartek J, Lune DP, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9.
23. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci USA 1990;88:5006-10.
24. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990;249:912-5.
25. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991;82:835-40.
26. Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Henessy C, et al. p53 expression in human breast cancer related to survival and prognostic factors. An immunohistochemical study. J Pathol 1991;164:75-81.
27. Starzynska T, Bromley M, Ghosh A, Sterm PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992;66:558-62.
28. Martin HM, Filipe MI, Morris RW, Lune DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992;50:859-62.
29. Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J.Cancer 1993;53:365-70.
30. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isoda J. Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992;84:883-7.
31. Frank JL, Bur ME, Garb JL, Kay S, Ware JL, Sismanis A, et al. p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 1994;73:181-6.
32. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994;54:321-6.
33. Frankel RH, Bayona W, Koslow M, Newcomb EW. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 1992;52:1427-33.